Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04806672
Other study ID # 695:12/2020
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date December 30, 2022

Study information

Verified date August 2022
Source Minia University
Contact Mohamed Mohamed
Phone 01019538266
Email mohamedhameed92@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Euthyroid sick syndrome (ESS) effects on patients suffering from traumatic brain injury (TBI) have received little attention. Moreover, there is limited evidence that serum levels of thyroid-related hormones might influence functional outcome in the acute phase of brain damage. However, the relationship is complex, and the relevance for functional outcome and the question of therapeutic interventions remain the subject of ongoing researches . Historically, a wide range of brain damage markers have been examined in TBI patients. However, owing to the limited tissue specificity and other concerns, most markers, including neuro-specific enolase and S100B protein, were compromised in routine clinical use . Glial fibrillary acidic protein (GFAP) was recently reported to have greater prognostic value than other biomarkers in TBI patients as a monomeric intermediate filament protein concentrated in the astroglial cytoskeleton; GFAP is specific to brain tissue and is not routinely found in peripheral blood circulation. However, GFAP is released after astrocyte death, making it an ideal candidate marker for brain injury patients . Several studies have found that the serum levels of GFAP on admission were significantly increased in TBI patients, also a correlation between serum concentrations and the pathological types of brain damage and clinical outcomes were also reported . However, the changes in serum GFAP over time and the associated predictive utility over the acute days post injury are largely unknown. To study the hypothesis of euthyroid sick syndrome (ESS) traumatic brain injury patients and its relation with GFAP.


Description:

After obtaining the approval of research ethical committee of faculty of medicine ,El-Minia university and taking informed written consent from the participants or their relatives, this prospective cross sectional non randomized observational study will be conducted in emergency ICU of anesthesiology and intensive care department in El-Minia university hospital ,on Patients suffering from isolated moderate to severe traumatic brain injury GCS (12-3) during the period from January2021 to December 2021. Based on inclusion and exclusion criteria, patients who met eligibility criteria, the prognosis and outcome of traumatic brain injury will be observed. Parameters assessed: Medical history Glasgow coma scale (GCS) on admission and daily Brain computerized tomography (CT) on admission ,3rd and 5th days Thyroid functions fT3, fT4, TSH and rT3.will be assessed on admission, after24h, 3rd and 7th days. APACHE II score ("Acute Physiology And Chronic Health Evaluation II ") Which will be assessed in admission day SOFA score The sequential organ failure assessment score (SOFA score), Which will be assessed every day. Glial fibrillary acidic protein (GFAP). On admission ,1st,3rd and 7th days Mechanical ventilation. Length of ICU Stay. Short term outcome after 28 days.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 30, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Age : between (18-60) years old. - Gender : both males and females. - Isolated moderate to severe traumatic brain injury(TBI) GCS (3-12) who is expected to survive for more than 24 hours Exclusion Criteria: - Poly trauma patients. - Critically ill patients. - Patients with history of endocrinal disturbance involving both hypothalamo-pituitary axis and thyroid gland. - Patients receiving antithyroid medication or hormonal replacement like thyroxin and insulin. - Pregnant and lactating females. - Patients with history neurological or psychiatric disorders. - Patients with liver or renal failure. - Patients with recent use of amiodarone or ß-blockers.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Minia University

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence to investigate the incidence of euthyroid sick syndrome (ESS) in traumatic brain injury patients. 1year
Primary morbidity and mortality to investigate the influence of euthyroid sick syndrome (ESS) on morbidity and mortality in traumatic brain injury patients. 1year
Secondary Disease relations to examine if there is any correlation between euthyroid sick syndrome (ESS) and Glial fibrillary acidic protein (GFAP) which is a sensitive biomarker for traumatic brain injury 1year